ES2123660T3 - Composiciones para administracion nasal que contienen metabolitos polares de analgesicos opioides. - Google Patents

Composiciones para administracion nasal que contienen metabolitos polares de analgesicos opioides.

Info

Publication number
ES2123660T3
ES2123660T3 ES93917408T ES93917408T ES2123660T3 ES 2123660 T3 ES2123660 T3 ES 2123660T3 ES 93917408 T ES93917408 T ES 93917408T ES 93917408 T ES93917408 T ES 93917408T ES 2123660 T3 ES2123660 T3 ES 2123660T3
Authority
ES
Spain
Prior art keywords
pct
agents
nasal administration
opioid analgesics
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93917408T
Other languages
English (en)
Inventor
Lisbeth Illum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Services Ltd
Original Assignee
Danbiosyst UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Danbiosyst UK Ltd filed Critical Danbiosyst UK Ltd
Application granted granted Critical
Publication of ES2123660T3 publication Critical patent/ES2123660T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Abstract

UNA COMPOSICION PARA ADMINISTRACION NASAL DE METABOLITOS POLARES DE ANALGESICOS OPIOIDES QUE COMPRENDE UN METABOLITO POLAR DE UN ANALGESICO OPIODE Y UN AGENTE QUE PROMOCIONA LA ABSORCION. SON METABOLITOS PREFERIDOS MORFINA MORFINA RIDO ES QUITOSAN PERO OTROS AGENTES ADECUADOS INCLUYEN POLIMEROS CATIONICOS, AGENTES BIOADHESIVOS, AGENTES ACTIVOS DE SUPERFICIE, ACIDOS GRASOS, AGENTES DE QUELACION, AGENTES MUCOLITICOS, CICLODEXTRINA, PREPARACIONES DE MICROESFERA O COMBINACIONES DE ELLOS.
ES93917408T 1992-02-05 1993-02-04 Composiciones para administracion nasal que contienen metabolitos polares de analgesicos opioides. Expired - Lifetime ES2123660T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929202464A GB9202464D0 (en) 1992-02-05 1992-02-05 Composition for nasal administration

Publications (1)

Publication Number Publication Date
ES2123660T3 true ES2123660T3 (es) 1999-01-16

Family

ID=10709891

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93917408T Expired - Lifetime ES2123660T3 (es) 1992-02-05 1993-02-04 Composiciones para administracion nasal que contienen metabolitos polares de analgesicos opioides.

Country Status (12)

Country Link
US (1) US5629011A (es)
EP (1) EP0625044B1 (es)
JP (1) JP3958352B2 (es)
AT (1) ATE171872T1 (es)
AU (1) AU665806B2 (es)
CA (1) CA2127805C (es)
DE (1) DE69321458T2 (es)
DK (1) DK0625044T3 (es)
ES (1) ES2123660T3 (es)
GB (2) GB9202464D0 (es)
NO (1) NO306283B1 (es)
WO (1) WO1993015737A1 (es)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1247472B (it) * 1991-05-31 1994-12-17 Fidia Spa Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
ES2194867T3 (es) * 1993-03-26 2003-12-01 Franciscus Wilhelmus He Merkus Composiciones farmaceuticas para la administracion intranasal de apomorfina.
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
GB2282758A (en) * 1993-08-23 1995-04-19 Euro Celtique Sa Oral morphine-6-glucuronide compositions
DE4403709A1 (de) * 1994-02-07 1995-08-10 Lohmann Therapie Syst Lts Pharmazeutische Zusammensetzung zur systemischen transdermalen Verabreichung mit dem Wirkstoff Morphin-6-glucuronid
US5543434A (en) * 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
US5679714A (en) * 1995-06-07 1997-10-21 Weg; Stuart L. Administration of ketamine for detoxification and treatment of tobacco addiction
WO1996002275A1 (fr) * 1994-07-20 1996-02-01 Toyama Chemical Co., Ltd. Onguent buccal a liberation prolongee
GB9416884D0 (en) * 1994-08-20 1994-10-12 Danbiosyst Uk Drug delivery compositions
GB9419979D0 (en) * 1994-10-04 1994-11-16 Medeva Holdings Bv Vaccine compositions
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
GB9522351D0 (en) * 1995-11-01 1996-01-03 Medeva Holdings Bv Vaccine compositions
US6017963A (en) * 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
GB9525083D0 (en) * 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
GB9606188D0 (en) * 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
US5976573A (en) * 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
US6248789B1 (en) 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US6403602B1 (en) * 1997-02-20 2002-06-11 The University Of Kentucky Research Foundation Morphine-6-sulfate analogues and their use for the treatment of pain
GB9710699D0 (en) 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
JP2005281315A (ja) * 1997-07-02 2005-10-13 Aventis Pharmaceuticals Holdings Inc 水性薬理組成物
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
AU747211B2 (en) * 1997-07-18 2002-05-09 Bayer Corporation Methods of removing residual solvent from nasal drug delivery compositions
JP4234803B2 (ja) * 1997-10-27 2009-03-04 久光製薬株式会社 薬物放出速度が制御された医薬組成物
FR2771929B1 (fr) * 1997-12-09 2001-02-23 Biovector Therapeutics Utilisation dans une composition pharmaceutique pour l'administration par voie nasale de particules hydrophiles pour la delivrance d'agents actifs au systeme nerveux central
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US6221378B1 (en) 1998-02-10 2001-04-24 Generex Pharmaceuticals Incorporated Mixed micellar delivery system and method of preparation
US7070799B1 (en) * 1998-02-10 2006-07-04 Generex Pharmaceuticals, Inc. Method for administering insulin to the buccal region
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
EP1056443B1 (en) * 1998-02-25 2004-05-06 Abbott Laboratories Butorphanol sustained release formulations
US6150420A (en) * 1998-06-01 2000-11-21 Theramax, Inc. Method for enhanced brain delivery of bupropion
US6608073B1 (en) 1998-10-14 2003-08-19 New Millennium Pharmaceutical Research, Inc. Intranasal codeine for the rapid suppression of cough and rapid relief of pain
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
FR2787029A1 (fr) * 1998-12-09 2000-06-16 Biovector Therapeutics Utilisation dans une composition pharmaceutique pour l'administration par voie nasale de vitamine b12 pour la delivrance d'agents actifs au systeme nerveux central
US7087215B2 (en) * 1998-12-21 2006-08-08 Generex Pharmaceuticals Incorporated Methods of administering and enhancing absorption of pharmaceutical agents
US6375975B1 (en) 1998-12-21 2002-04-23 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary application
US6849263B2 (en) * 1998-12-21 2005-02-01 Generex Pharmaceutical Incorporated Pharmaceutical compositions for buccal delivery of pain relief medications
US6451286B1 (en) 1998-12-21 2002-09-17 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds
GB9908921D0 (en) * 1999-04-19 1999-06-16 Britannia Pharmaceuticals Ltd Spray dispenser for opiod antagonists
WO2000076477A1 (en) * 1999-06-16 2000-12-21 Nastech Pharmaceutical Co., Inc. Methods and compositions for treating breakthrough pain
US6225343B1 (en) 1999-06-16 2001-05-01 Nastech Pharmaceutical Company, Inc. Compositions and methods comprising morphine gluconate
EP1183027A4 (en) * 1999-06-16 2003-02-05 Nastech Pharmaceutical Co PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRA-NASAL DELIVERY MORPHINE
GB9924797D0 (en) * 1999-10-20 1999-12-22 West Pharm Serv Drug Res Ltd Compound
US6863896B1 (en) * 1999-10-26 2005-03-08 Chiron Corporation Plant lectins as mucosal adjuvants
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
KR20130010512A (ko) 1999-10-29 2013-01-28 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
PL357158A1 (en) 2000-02-08 2004-07-12 Euro-Celtique, S.A. Controlled-release compositions containing opioid agonist and antagonist
OA12215A (en) * 2000-02-08 2006-05-09 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations.
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
US20020013331A1 (en) 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
US8257744B2 (en) 2000-07-07 2012-09-04 Laboratorios Farmacéuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
FR2811227A1 (fr) * 2000-07-07 2002-01-11 Philippe Maincent Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs
AU2001286518A1 (en) * 2000-08-15 2002-02-25 University Of Kentucky Research Foundation Programmable multi-dose intranasal drug delivery device
EP1337244A4 (en) 2000-10-30 2006-01-11 Euro Celtique Sa HYDROCODON FORMULATIONS WITH CONTROLLED RELEASE
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
US20030044356A1 (en) * 2001-04-20 2003-03-06 Jin Auh Composition for nasal solution sprays having effective component of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one)
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
EP1406630A1 (en) * 2001-07-06 2004-04-14 Endo Pharmaceuticals Inc. Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic
US8329216B2 (en) * 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
WO2003015744A1 (en) 2001-08-16 2003-02-27 Medical Research Council Chitin microparticles and their medical uses
CA2459976A1 (en) * 2001-09-26 2003-04-03 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
US20140271788A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Sublingual and buccal film compositions
WO2003066068A1 (en) * 2002-02-01 2003-08-14 Intradigm Corporation Hpma-polyamine conjugates and uses therefore
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
US20040077540A1 (en) * 2002-06-28 2004-04-22 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
JP2006021996A (ja) * 2002-07-04 2006-01-26 Dainippon Sumitomo Pharma Co Ltd 置換ヒドロキシピリジン化合物の抱合体
EP2422772A3 (en) * 2002-09-20 2012-04-18 Alpharma, Inc. Sequestering subunit and related compositions and methods
DE10248601B4 (de) * 2002-10-17 2006-05-24 Goldstein, Naum, Dr.habil.nat. Pharmazeutisches Mittel zur endonasalen Applikation bei der Behandlung von Krankheiten und Störungen des zentralen Nervensystems
US7445769B2 (en) * 2002-10-31 2008-11-04 Cadbury Adams Usa Llc Compositions for removing stains from dental surfaces and methods of making and using the same
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
GB0302738D0 (en) * 2003-02-06 2003-03-12 Advanced Biopolymers As Composition
EP1620732A2 (en) * 2003-04-30 2006-02-01 Nastech Pharmaceutical Company Inc. Claudins' underexpression as markers of tumor metastasis
AU2004235744A1 (en) * 2003-05-01 2004-11-18 Archimedes Development Limited Nasal administration of the LH-RH analog leuprolide
US20060263350A1 (en) * 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
US7968122B2 (en) * 2003-12-10 2011-06-28 Adventrx Pharmaceuticals, Inc. Anti-viral pharmaceutical compositions
US20050129679A1 (en) * 2003-12-15 2005-06-16 Nastech Pharmaceutical Company Inc. Method for opening tight junctions
GB0400804D0 (en) 2004-01-14 2004-02-18 Innoscience Technology Bv Pharmaceutical compositions
US20050175679A1 (en) * 2004-02-10 2005-08-11 Michael Moshman Controlled release formulations
GB0403938D0 (en) * 2004-02-21 2004-03-24 West Pharm Serv Drug Res Ltd Chitosan containing solution
US20050283004A1 (en) * 2004-06-18 2005-12-22 Hopax Chemicals Manufacturing Co., Ltd. Alkylsulfonated polyaminosaccharides
GB0416328D0 (en) * 2004-07-21 2004-08-25 Univ Cardiff Use of dry powder compositions for pulmonary delivery
US7641892B2 (en) * 2004-07-29 2010-01-05 Cadburry Adams USA, LLC Tooth whitening compositions and delivery systems therefor
US7115561B2 (en) * 2004-09-22 2006-10-03 Patterson James A Medicament composition and method of administration
WO2006084082A1 (en) * 2005-02-03 2006-08-10 Duramed Pharmaceuticals, Inc. Compositions of unconjugated estrogens and methods for their use
ATE458491T1 (de) 2005-08-26 2010-03-15 Univ Leland Stanford Junior Verfahren zur behandlung von kopfschmerzen durch verabreichung von oxytocin
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
AU2007285472B2 (en) * 2006-03-30 2013-10-24 Engene, Inc. Non-viral compositions and methods for transfecting gut cells in vivo
MX2008016372A (es) 2006-06-19 2009-05-28 Alpharma Inc Composiciones farmaceuticas.
US20080075771A1 (en) * 2006-07-21 2008-03-27 Vaughn Jason M Hydrophilic opioid abuse deterrent delivery system using opioid antagonists
US20080233156A1 (en) * 2006-10-11 2008-09-25 Alpharma, Inc. Pharmaceutical compositions
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
WO2008091588A1 (en) 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
US20090124650A1 (en) * 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
US8802156B2 (en) 2007-11-14 2014-08-12 Laboratorios Farmacéuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
CA2709905A1 (en) * 2007-12-17 2009-06-25 Alfred Liang Abuse-resistant oxycodone composition
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20150018379A1 (en) 2011-05-13 2015-01-15 Euro-Celtique S.A. Intranasal Pharmaceutical Dosage Forms Comprising Naloxone
WO2013011477A1 (en) 2011-07-20 2013-01-24 Torrent Pharmaceuticals Ltd Pharmaceutical invention of tapentadol
CN106414415A (zh) 2014-03-14 2017-02-15 北卡罗来纳大学教堂山分校 用于抑制雄性生育力的小分子
CN107847552B (zh) 2015-01-07 2022-07-01 三叉神经股份公司 含镁的催产素制剂和使用方法
FR3032353B1 (fr) 2015-02-06 2017-03-10 Jacques Seguin Composition pharmaceutique et dispositif pour le traitement de la douleur
CA3041309A1 (en) * 2016-10-21 2018-04-26 Somniferum Labs LLC Compositions, methods and kits for the safe inhaled delivery of targeted opioids for the treatment of pain and addiction
US10292948B2 (en) 2017-01-11 2019-05-21 Torrent Pharmaceuticals Limited Tapentadol nasal composition
FI3568126T3 (fi) 2017-01-11 2024-01-24 Torrent Pharmaceuticals Ltd Nenään annosteltavia tapentadolikoostumuksia
US11304968B2 (en) 2018-11-16 2022-04-19 Janssen Pharmaceutica Nv Pharmaceutical compositions comprising a hydroxyethylquercetin glucuronide
US10639294B2 (en) 2018-10-02 2020-05-05 Janssen Pharmaceutica Nv Pharmaceutical compositions comprising a hydroxyethylquercetin glucuronide metabolite
CN110257025B (zh) * 2019-07-03 2020-07-03 中国石油大学(华东) 水基钻井液用环糊精微球超高温降滤失剂及其制备方法以及水基钻井液和应用
EP4230206A1 (en) * 2020-10-15 2023-08-23 Pharmbiotest Poland SP.ZO.O. Pharmaceutical composition based on nalbuphine and/or its salts for nasal administration

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
DE3602370A1 (de) * 1986-01-27 1987-08-06 Chrubasik Sigrun Verwendung von analgetica durch inhalation
GB8918879D0 (en) * 1989-08-18 1989-09-27 Danbiosyst Uk Pharmaceutical compositions
US5240932A (en) * 1990-03-30 1993-08-31 Yasunori Morimoto Percutaneously absorbable compositions of morphine or analogous analgesics of morphine
FR2665357B1 (fr) * 1990-07-31 1995-03-31 Aiache Jean Marc Procede de preparation d'une forme galenique bio-adhesive et forme galenique ainsi preparee.
WO1993021188A1 (en) * 1992-04-13 1993-10-28 Regents Of The University Of Minnesota Delta opioid receptor-selective benzylidene-substituted morphinans for the treatment of alcohol abuse

Also Published As

Publication number Publication date
EP0625044B1 (en) 1998-10-07
US5629011A (en) 1997-05-13
JPH07503481A (ja) 1995-04-13
CA2127805C (en) 2004-03-30
CA2127805A1 (en) 1993-08-19
GB9413102D0 (en) 1994-08-31
DK0625044T3 (da) 1999-06-21
WO1993015737A1 (en) 1993-08-19
NO942787D0 (no) 1994-07-27
AU665806B2 (en) 1996-01-18
GB2277682A (en) 1994-11-09
ATE171872T1 (de) 1998-10-15
DE69321458T2 (de) 1999-03-18
DE69321458D1 (de) 1998-11-12
JP3958352B2 (ja) 2007-08-15
NO942787L (no) 1994-07-27
AU3458093A (en) 1993-09-03
EP0625044A1 (en) 1994-11-23
NO306283B1 (no) 1999-10-18
GB2277682B (en) 1995-12-20
GB9202464D0 (en) 1992-03-18

Similar Documents

Publication Publication Date Title
ES2123660T3 (es) Composiciones para administracion nasal que contienen metabolitos polares de analgesicos opioides.
ATE333867T1 (de) Emulgierte arzneistoffabgabesysteme
DK0799024T3 (da) Farmaceutisk aerosol indeholdende mindst en sukker
ES2118677T3 (es) Una composicion que comprende un agente activo disuelto en un vehiculo formador de vidrio y un procedimiento para su preparacion.
GEP20022709B (en) Pharmaceutical Compositions Having Appetite Suppressant Activity
DK0697858T3 (da) Nasalt medikamentafgivelsessystem indeholdende nikotin
EP0679390A3 (en) Sprayable topical pharmaceutical compositions
ES2118263T3 (es) Dispositivo de liberacion que tiene excipientes encapsulados.
GR3033301T3 (en) Medicament form for the delivery of active substances to wounds
GR3030084T3 (en) Sprayable film forming system releasing active substances for use on plants
DK0636020T3 (da) Farmaceutisk bærersystem indeholdende definerede lipider
CA2182004A1 (en) Film Coated Tablet of Paracetamol and Domperidone
KR950028767A (ko) 피부통과 투약을 위한 신규의 약제학적 투여 형태
ES2090712T3 (es) Medicamento agudo que contiene ibuprofeno y su uso.
RS50298B (sr) Direktno kompresibilna matrica za kontrolisano oslobađanje pojedinačnih dnevnih doza klaritromicina
BR9506279A (pt) Composição para uso em um sistema de liberação de droga transdérmica sistema de liberação transdérmica processo de administração de estrogênio através da pele e uso de um sistema de liberação transdérmica
CA2129527A1 (fr) Composition pharmaceutique utilisable comme analgesique contenant l'acide (benzoyl-3 phenyl)-2 propionique-(r)
MX9302986A (es) Medicamento que contiene metrifonato y procedimiento para su preparacion
ES2082523T3 (es) Un medicamento de accion retardada que contiene ibuprofen y su empleo.
UA41378C2 (uk) Здатний до емульгування у воді рідкий засіб з інсектицидною активністю
AU9221898A (en) Pharmaceutical coating composition and method of use
WO1996001128A3 (de) Niedrig dosierte steroidtabletten, die gallussäureester als antioxidans enthalten, verfahren zur herstellung und die verwendung

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 625044

Country of ref document: ES